Financing Drug Innovation in the US: Current Framework and Emerging Challenges

Area of Science:

• * Pharmaceutical Economics
• * Health Policy
• * Drug Development

Background:

• * The US drug innovation financing framework relies on marketing exclusivity and competition to drive private sector investment and R&D.
• * This system aims to balance return on investment (ROI) for innovation with patient access to new therapies.
• * The core approach has remained consistent since the 1980s, with some adjustments for biosimilars.

Purpose of the Study:

• * To review the key components of the current US drug innovation financing system.
• * To analyze how the system balances multiple objectives, including investment incentives and patient access.
• * To identify emerging challenges and the need for future adaptation.

Main Methods:

• * Review of the existing US drug innovation financing framework.
• * Analysis of the system's historical evolution and current provisions.
• * Examination of challenges posed by new therapeutic modalities.

Main Results:

• * The current system incentivizes R&D through exclusivity and competition, but faces challenges with high-cost, single-administration therapies like gene therapy.
• * The framework needs to remain adaptable to diverse scientific approaches and economic conditions.
• * Predictability for investors and payers is crucial for long-term development and coverage decisions.

Conclusions:

• * The US drug innovation financing system requires ongoing evaluation and adaptation to ensure continued development and patient access to novel therapies.
• * Experimentation and stakeholder input are essential for addressing challenges posed by advanced treatments.
• * Future financing models must accommodate transformative, high-investment therapies.